COMMUNIQUÉS West-GlobeNewswire
-
Akebia Therapeutic’s Vafseo® (vadadustat) Granted Additional Patent
17/11/2026 -
Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR®
17/11/2026 -
Windward Bio to Participate at the Jefferies London Global Healthcare Conference
17/11/2026 -
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
17/11/2026 -
SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering
17/11/2026 -
COP31 : l’EAACI appelle à intégrer les allergies et la santé respiratoire dans les politiques de lutte contre le changement climatique
17/11/2026 -
Non-Surgical Hair Restoration in NYC: Park Avenue Practice Opens Dedicated GLP-1 Hair Loss Assessments for January, With Procedure Decided Only After Blood Work
17/11/2026 -
Terumo Neuro Announces Publication of RESTORE Registry Results in the Journal of NeuroInterventional Surgery
17/11/2026 -
Newly Launched CuraeChoice Platform Unlocks Healthcare Pricing Visibility for Nearly 370,000 Employers by Tax ID Alone
17/11/2026 -
Dazed, Inc. Reports 72.5% Gross Margin and 121% Royalty Growth as Texas Lawmakers File Adult-Use Cannabis Bills in Home Market
17/11/2026 -
Priavoid Announces Topline Phase 2 Data for Oral All-D-Peptide PRI-002 in Alzheimer’s Disease at CTAD 2026
17/11/2026 -
MATTER Honors Companies Turning Employee Activation Into Community Impact
17/11/2026 -
Edesa Biotech Granted Orphan Designation for Paridiprubart for the Treatment of ARDS by the European Commission
17/11/2026 -
L’EAACI fait le lien entre la recherche sur les allergies et l’action publique en matière d’anaphylaxie à Utrecht
17/11/2026 -
From National Geographic to Forbes: Kraig Biocraft Builds Visibility as Spider Silk Commercialization Advances
17/11/2026 -
OneMedNet Reports Third Quarter 2026 Financial Results and Reiterates Fourth Quarter 2026 Outlook
17/11/2026 -
Pharmascience Canada launches a new product
17/11/2026 -
Pharmascience Canada lance un nouveau produit
17/11/2026 -
Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors
17/11/2026
Pages